Vaccine for dementia to enter human trials after successful tests on mice
‘This could be revolutionary,’ says lead researcher as treatment found to remove causes of brain decline
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A vaccine designed to prevent dementia is to enter human trials after successful tests on mice.
If the treatment is proven to work safely on people it could be available within a decade, researchers say.
The revelation, published in the journal Alzheimer’s Research & Therapy, comes after 20 years of research backed by the US government and largely carried out in Australia.
The treatment – a combination of two different drugs – is said to work by targeting and then removing the brain plaque and nanofibre tangles which lead to cognitive decline and memory failure.
It also has the potential to prevent Alzheimer’s in people who are predisposed to the disease, researchers say.
It is said to be unlike anything currently available, because the most medicines have achieved so far is to reduce symptoms rather than targeting the specific problems affecting the brain.
Professor Nikolai Petrovsky, a specialist in endocrinology at Flinders University in Adelaide, where much of the work is being carried out, said: “This vaccine could be revolutionary. It’s not something that will be available tomorrow, but it’s an exciting step in the right direction.”
He told Australia’s Daily Telegraph: “This is not the start of the journey, it’s the end.”
And he added he was now optimistic human trials will have started within 20 months.
However, there may be reason for caution, as several promising drugs said to help with dementia have previously failed clinical trials.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments